Search In this Thesis
   Search In this Thesis  
العنوان
The Value of Arm Lymphatic Mapping Using Blue Dy Technique in Prevention of Lymphedema During Axillary Lymph Node Dissection for Breast Carcinoma /
المؤلف
Ahmed, Alaa Eldin Hussien.
هيئة الاعداد
باحث / علاء الدين حسين احمد
مشرف / مدحت خفجى
مشرف / اسامة الملط
مشرف / محمد شعلان
الموضوع
Leukemia, Monocytic, Acute.
تاريخ النشر
2013.
عدد الصفحات
145 P. :
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
علم الأورام
تاريخ الإجازة
1/1/2013
مكان الإجازة
جامعة القاهرة - معهد الأورام القومى - جراحة الاورام
الفهرس
Only 14 pages are availabe for public view

from 170

from 170

Abstract

Axillary Dissection Is Still Regarded As A Staging Procedure In Cases With Breast Cancer That Provides Important Prognostic Information And Also Maintains Local Axillary Control But Results In Many Side Effects With Lymphedema Being The Most Devastating Complication Of Axillary Lymph Node Dissection With No Successful Treatment For Lymphedema, Prevention Is The Key To Avoid It. Sentinel Lymph Node Biopsy Was Essentially Developed To Prevent Lymphedema But Still The Lymphedema Rates With SLN Ranges About 7 %Even In Most Experienced Hands Reversed Mapping Using Patent Blue Dye Is A New Technique That Aims To Identify And Protect Sentry Node Draining The Upper Limbs With Removal Of All Breast Related Nodes. Through This Technique The Surgeon Is Able To Outline Upper Limb Lymphatics And Lymph Nodes And Avoid Their Removal And Hence Prevent Lymphedema.Through This Prospective Study Done On 75 Breast Cancer Patients In The National Cancer Institute, We Explore This New Technique And We Evaluated The Identification Rates, Possibility Of Lymphatics And Nodes Preservation,Cross Over Between Upper Limb And Breast Lymph Nodes, Oncological Safety Of The Technique And Reviewing Different Literature To Compare Our Results With Available Results ,Also Mentioning The New Modifications On This Technique Aiming At Better Identification Rates And Ultimately Better Prevention Of Upper Limb Post Mastectomy Lymphedema.III.